COCP — Cocrystal Pharma Income Statement
0.000.00%
Last trade - 00:00- $15.46m
- $5.60m
Annual income statement for Cocrystal Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2.01 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 11.6 | 14.2 | 38.8 | 18.6 | 17.9 |
| Operating Profit | -9.59 | -14.2 | -38.8 | -18.6 | -17.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -9.65 | -14.2 | -38.8 | -18 | -17.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -9.65 | -14.2 | -38.8 | -18 | -17.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -9.65 | -14.2 | -38.8 | -18 | -17.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -9.65 | -14.2 | -38.8 | -18 | -17.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.1 | -1.93 | -2.23 | -2.13 | -1.72 |